Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DLI plus blinatumomab for resistant mixed chimerism or minimal residual disease after allogeneic transplant in B-precursor ALL
2017-002314-31Phase 2Terminated
- Sponsor
- LMU Klinikum
- Start
- May 2018
- Modality
- Cell Therapies, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab and donor lymphocytes in acute lymphoblastic leukemia (ALL), sponsored by LMU Klinikum. Primary endpoint: Incidence and grade of adverse events including graft-versus-host disease. Started May 2018; status: terminated.
02
Drugs
blinatumomabdonor lymphocytes
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on 2017-002314-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002314-31.